Eli Lilly & Co.'s Mounjaro, a drug for obesity treatment, experienced a notable sales decline in March, with revenues dropping to ₹114 crore ($12.3 million) from ₹135 crore the previous month. This decline is attributed to the influx of generic versions of Novo Nordisk A/S's semaglutide, which saw its market share in India's GLP-1 segment rise to 33% from 25%. Mounjaro's share fell from 71% to 64%, indicating a significant impact from the generics. The patent for semaglutide expired on March 20, leading to a rapid rollout of cheaper alternatives, with Torrent Pharmaceuticals emerging as the largest local competitor, holding an 8% market share. The surge in demand for semaglutide generics is expected to continue, prompting a price war that could reshape the obesity treatment landscape in India. Novo has also announced price reductions for its products to remain competitive in this changing market.